Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
Your provider adjusts the protocol as your results come in, keeping you in the therapeutic range as your goals evolve
Ten produkt jest niedostpny
Studies suggest that certain peptides may help reduce inflammation in the gut, speed up the healing of intestinal wounds, and improve overall gut integrity
Furthermore, in the studies by Borgstrm et al
Owing to this, adhering to healthy lifestyle choices with a balanced diet as well as a commitment to regular physical activity is important to preserve the results of the procedure